Pulst and Scoles Laboratories

Spinocerebellar ataxia 4 is a severe progressive movement disease that can begin as early as the late teens. Now, a multinational research team led by University of Utah researchers has...

The gift of $1 million has created the Dale L. Rindlisbacher Endowed Chair in Neurodegeneration Research, with Stefan M. Pulst, MD, Dr Med, Chair of the Department of Neurology, as...

Scientists at University of Utah Health made a discovery that could lead to a new way to treat Parkinson's disease and potentially stop its progression.

U of U Health scientists have identified a molecule that slows cells’ production of alpha-synuclein, a protein that forms toxic aggregates in the brains of people with Parkinson’s disease.

Discoveries from the laboratory of Stefan Pulst, Dr Med, on a rare disease, ataxia, has led to a potential treatment for another devastating neurological condition, ALS.

Scientists report for the first time that a protein, called Staufen1, accumulates in cells of patients suffering from degenerative ataxia or amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's...